MedTrace Logo

Real World Study With Benralizumab in Severe Asthma in Switzerland

NCT03907137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2024-02-29

No results posted yet for this study

Summary

BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1 to 16 weeks post-treatment initiation including use of OCS. The generated data on the time of asthma symptom relief after initiation of benralizumab will support patient management for a better disease control in severe asthma patients under benralizumab treatment. To assess long term outcomes the patients will have a last mandatory visit after 56 weeks, with no visits scheduled between week 16 and 56.

Conditions

  • Severe Eosinophilic Asthma

Sponsors & Collaborators

Principal Investigators

  • Thomas Rothe, Dr. med. · Kantonsspital Graubünden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-21
Primary Completion
2023-01-04
Completion
2023-01-04

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907137 on ClinicalTrials.gov